MOUD Buprenorphine Sublocade denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for moud buprenorphine sublocade are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Sublocade on Medical-Necessity Grounds — and How to Overturn It

A medical-necessity denial for Sublocade means UnitedHealthcare's reviewer determined the clinical record did not sufficiently establish that the injectable extended-release buprenorphine formulation is necessary for this patient's treatment of opioid use disorder (OUD). These denials are often driven by missing or incompletely submitted documentation rather than by actual clinical unsuitability — which means a well-documented appeal has a strong chance of reversal.

## Why This Denial Is Appealable

Opioid use disorder is a chronic relapsing condition, and medication for opioid use disorder (MOUD) is a cornerstone of evidence-based treatment supported by SAMHSA, ASAM, and the American Society of Addiction Medicine. Extended-release injectable buprenorphine is distinct from sublingual formulations because it removes the requirement for daily adherence and eliminates diversion risk — factors that are directly clinically relevant for many patients. A denial that ignores those distinctions is subject to challenge.

Federal parity law (MHPAEA) also prohibits placing more burdensome medical-necessity criteria on substance use disorder treatment than on analogous medical/surgical treatment. If the plan's criteria are disproportionately restrictive, that is an independent appeal ground.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): Submit a written internal appeal within the timeframe on your denial letter. Request a peer-to-peer call between your prescriber and the plan's medical director simultaneously.
• External review: After exhausting internal review, you have the right to independent external review. Under ACA §2719, the window is generally up to four months from the internal denial notice.
• Expedited appeal: If the patient's clinical situation is urgent, the prescriber can request an expedited determination, typically resolved within 72 hours.

## Concrete Appeal Steps

1. Retrieve the denial letter and identify exactly which medical-necessity criteria UHC says were unmet. 2. Download UHC's current published coverage policy for Sublocade (available on uhcprovider.com) and map every stated requirement. 3. Ask the prescriber to draft a targeted letter that addresses each unmet criterion head-on, citing specific chart findings. 4. Compile the documentation package below. 5. File the written appeal with the criteria-mapping table as a cover sheet.

## Documentation to Gather

• Diagnosis confirmation: Documented DSM-5 diagnosis of moderate-to-severe OUD, including assessment date.
• Prior treatment history: A timeline of prior MOUD trials or other treatment attempts, with dates, formulations used, documented outcomes, and reasons for transition — specifically any adherence or safety concerns with sublingual buprenorphine.
• Clinical severity documentation: Recent prescriber notes, assessment scores (by name of instrument only, not raw numbers unless part of the chart record), and any documented relapse or near-relapse events.
• Prescriber medical-necessity letter: Should state the clinical rationale for the injectable formulation specifically, referencing applicable ASAM/SAMHSA guidelines by organization name, and should confirm the patient meets the criteria stated in the FDA-approved prescribing label for Sublocade — directing reviewers to that label for the exact eligibility requirements.
• Pharmacy/dispensing records: If relevant, showing prior sublingual fill history.

## Criteria-Mapping Structure

Create a table with three columns: (1) UHC policy requirement, (2) corresponding FDA label criterion, (3) chart evidence that satisfies it. Address every row. Reviewers frequently uphold denials simply because the documentation was submitted without this explicit cross-reference.